FDA Critical Path Tools/Biomarkers

Toxicity Screening & Selectivity Profiling of Cardiac Ion Channels

Systems: PatchXpress® 7000A or QPatch (FASTPatch® Assay)

Over-dependence on the hERG assay as a preclinical cardiac risk indicator can terminate development of potentially useful compounds that non-selectively block hERG and other compensatory (e.g., voltage-gated Na+ and Ca2+) channels. Conversely, some compounds may pose a safety risk by prolonging repolarization via interactions with non-hERG cardiac channels. Automated patch clamp screening and concentration-response assays provide a rapid, comprehensive survey of cardiac channels for greater insight into potential cardiac risk and more effective decision-making in early preclinical development.

Assay Features:

• Complements S7B integrated cardiac risk assessment
• Provides mechanistic interpretation
• Predicts proarrhythmia potential
• Fully validated by ChanTest’s expert electrophysiologists

For a quote or additional information, please email inquiries@chantest.com or call 216-332-1665.

Additional Cardiac Safety Assays:

• hERG Concentration Response Assay
• Cardiac Ion Channel Assays
• Action Potential Assays
• Trafficking Assays